^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    16h
    PIPSeN: Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=600 --> 180 | Unknown status --> Terminated; study design, change of standard of care, enrollment difficulties
    Enrollment change • Trial termination • Platinum sensitive
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation
    |
    Lynparza (olaparib)
    1d
    Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (clinicaltrials.gov)
    P3, N=220, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab)
    1d
    CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Mar 2029 --> Oct 2026
    Trial completion date • Checkpoint inhibition • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    4d
    Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation. (PubMed, Clin Lung Cancer)
    RBM10 mutation is frequent in Japanese patients with NSCLC with EGFR mutation, especially those with L858R or uncommon mutations, and was associated with late-onset and features of indolent tumor growth.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • RBM10 (RNA Binding Motif Protein 10)
    |
    TP53 mutation • EGFR mutation • EGFR L858R
    |
    Tagrisso (osimertinib)
    4d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Nov 2036 --> Dec 2031 | Trial primary completion date: Nov 2036 --> Dec 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    4d
    A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=190, Not yet recruiting, Zhejiang Anglikang Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    4d
    A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Dec 2025
    Trial primary completion date • IO biomarker
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab)
    5d
    Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Merus B.V. | Initiation date: Dec 2025 --> Mar 2025
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • petosemtamab (MCLA-158)
    5d
    Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (clinicaltrials.gov)
    P2, N=156, Recruiting, Swiss Cancer Institute | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Sep 2030 | Trial primary completion date: Mar 2028 --> Sep 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)
    6d
    Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (clinicaltrials.gov)
    P3, N=163, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab)
    6d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=387, Recruiting, Pfizer
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    6d
    D702KC00001: A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) (2024-519786-22-01)
    P1/2, N=43, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)